RxDoctor Payments Data

Benjamin Watson, MD

Internal Medicine · Savannah, GANPI 1124027842

Payments from drug & device makers

$14,409in general payments, 2019–2025

Across 262 payments — averaging $55.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$6K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Intuitive Surgical$1K
  • Novartis$745
  • Novo Nordisk$742
  • Lilly USA, LLC$289
  • plus $2K from 42 others

What the payments were for

  • Speaking & faculty fees$6,25043%
  • Food & beverage$4,15329%
  • Education$1,0007%
  • Gifts$3,00621%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,409 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$227,465
Medicare patients
400
Services billed
9,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide120$187,058
JanuviaSitagliptin Phosphate83$109,621
JardianceEmpagliflozin83$83,721
TrulicityDulaglutide66$81,079
FarxigaDapagliflozin Propanediol53$66,899
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$25,163
EliquisApixaban26$23,828
MounjaroTirzepatide15$22,532
Tresiba Flextouch U-100Insulin Degludec44$21,849
Bydureon BciseExenatide Microspheres20$14,636
Tresiba Flextouch U-200Insulin Degludec11$9,594
Novolog FlexpenInsulin Aspart43$8,067
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$7,854
XareltoRivaroxaban26$7,377
Breo ElliptaFluticasone/Vilanterol15$7,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$742$187,058120 claims
MerckJanuvia$14$109,62183 claims
Lilly USA, LLCTrulicity, Mounjaro$289$103,61281 claims
Boehringer IngelheimJardiance$139$83,72183 claims
AstraZenecaFarxiga$184$66,89953 claims
GSKTrelegy Ellipta, Breo Ellipta$60$32,18147 claims
PfizerEliquis$6,387$23,82826 claims
AbbVieSynthroid$183$3,07357 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →